A retrospective study of efficacy of anti-programmed death-1 (PD-1) monotherapy or nivolumab in combination with ipilimumab in metastatic melanoma patients
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2022 New trial record